Evidence map›Paper›PMID 28377128›Full record

ArticleNeurobiology of disease2017

Enhanced AMPA receptor-mediated neurotransmission on CA1 pyramidal neurons during status epilepticus.

Suchitra Joshi, Karthik Rajasekaran, Huayu Sun, John Williamson, Jaideep Kapur

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Overactive EAAT1 ClActa neuropathologica communications · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Why ketamine.Epilepsy & behavior : E&B · 2023
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Suchitra JoshiDepartment of Neurology, University of Virginia, Charlottesville, VA 22908, United States.
Karthik RajasekaranDepartment of Neurology, University of Virginia, Charlottesville, VA 22908, United States.
Huayu SunDepartment of Neurology, University of Virginia, Charlottesville, VA 22908, United States.
John WilliamsonDepartment of Neurology, University of Virginia, Charlottesville, VA 22908, United States.
Jaideep KapurDepartment of Neurology, University of Virginia, Charlottesville, VA 22908, United States; Department of Neuroscience University of Virginia, Charlottesville, VA 22908, United States. Electronic address: jk8t@virginia.edu.
University of Virginia · US

Funding

TREATMENT OF STATUS EPILEPTICUSR01NS040337 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KAPUR, JAIDEEP · 2000 to 2021
$5.0M
Neurosteroid Regulation of SeizuresR01NS044370 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KAPUR, JAIDEEP · 2003 to 2017
$4.1M
NINDS NIH HHS R01 NS040337NINDS NIH HHS R01 NS044370
6 · The paper itself

Abstract

Status epilepticus (SE) is a common neurological emergency that results from the failure of the mechanisms responsible for seizure termination or the initiation of mechanisms that lead to abnormally prolonged seizures. Although the failure of inhibitory mechanisms during SE is well understood, the seizure-initiating mechanisms are poorly understood. We tested whether hippocampal α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated transmission was enhanced during SE and assessed the underlying molecular mechanism. In animals in self-sustaining limbic SE the amplitudes of the miniature, spontaneous, and AMPA-evoked excitatory currents recorded from the CA1 pyramidal neurons were larger than those recorded in the controls. The evoked EPSCs rectified inwardly. In these animals, the surface expression of GluA1 subunit-containing AMPARs was increased in the CA1 pyramidal neurons. The phosphorylation of the GluA1 subunit on S831 and S845 residues was reduced in animals in SE. In contrast, the GluA1 subunit surface expression and AMPAR-mediated neurotransmission of dentate granule cells (DGCs) was not altered. Treating animals in SE with the NMDAR antagonist MK-801 or with diazaepam blocked the increased surface expression of the GluA1 subunits. NMDAR blockade also prevented the dephosphorylation of the S845 residue but not that of S831. Targeting NMDARs and AMPARs may provide novel strategies to treat benzodiazepine-refractory SE.

Indexed as

AnimalsCA1 Region, HippocampalExcitatory Amino Acid AntagonistsExcitatory Postsynaptic PotentialsMaleNeuronsOrgan Culture TechniquesPyramidal CellsRatsRats, Sprague-DawleyReceptors, AMPAStatus EpilepticusSynaptic TransmissionExcitatory Amino Acid AntagonistsReceptors, AMPAAMPA receptorBenzodiazepinesGluA1 subunit phosphorylationmEPSCsMK-801Status epilepticus

Identifiers

PMID28377128
PMCPMC5481781
OpenAlexW2598942970

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.